Zobrazeno 21 - 30
of 100
pro vyhledávání: '"Andy I. Chen"'
Autor:
Andy I. Chen
Publikováno v:
Blood and Marrow Transplant Handbook ISBN: 9783030536251
Hematopoietic cell transplantation (HCT) is a key treatment modality in the management of advanced Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Autologous HCT (autoHCT) can be curative for relapsed or refractory HL and diffuse large B-cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcfc80214089a5de657e3dbb99c6539d
https://doi.org/10.1007/978-3-030-53626-8_17
https://doi.org/10.1007/978-3-030-53626-8_17
Autor:
Brandon Hayes-Lattin, Richard T. Maziarz, Andy I. Chen, Eneida R. Nemecek, Catherine R. Murphree, Levanto Schachter, Phillip W. Raess, Sarah J. Nagle
Publikováno v:
Transplantation and Cellular Therapy. 27:S390-S391
Autor:
Andy I. Chen, Jian Chen, Runzhuo Ma, Andrew J. Hung, Erik Vanstrum, Shubham Bhatia, Ryan Lee, Jessica H. Nguyen
Publikováno v:
Journal of Urology. 203
Autor:
Gunjan L. Shah, Umar Farooq, Sairah Ahmed, Sameh Gaballa, Andy I. Chen, Kwang Woo Ahn, Rammurti T. Kamble, Brian K. Link, Timothy S. Fenske, Nina Shah, Andrew R. Rezvani, Jonathan W. Friedberg, Edward A. Copelan, Carla Casulo, Mehdi Hamadani, Aaron Cumpston, Aleksandr Lazaryan, Yogesh Jethava, Hillard M. Lazarus, Vaishalee P. Kenkre, Siddhartha Ganguly, Basem M. William, David A. Rizzieri, Richard F. Olsson, Jonathon B. Cohen, Cesar O. Freytes, Anna Sureda, Hannah Choe, Andrew D. Zelenetz, Sonali M. Smith, Alyssa DiGilio, Sachiko Seo, Mahmoud Aljurf, Melham M. Solh, David J. Inwards, Christopher R. Flowers
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:1163-1171
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (C
Autor:
Sairah Ahmed, Nelli Bejanyan, Veronika Bachanova, Andy I. Chen, Stefan O. Ciurea, Kwang Woo Ahn, Zachariah DeFilipp, Andrew R. Rezvani, Timothy S. Fenske, Alex F. Herrera, Minoo Battiwalla, Mehdi Hamadani, Hillard M. Lazarus, Hemant S. Murthy, Leona Holmberg, Javier Bolaños-Meade, Anita D'Souza, Nirav N. Shah, Edmund K. Waller, Anna Sureda, Bipin N. Savani, Parastoo B. Dahi, Matthew L. Ulrickson, Nasheed Hossain, Narendranath Epperla, Nosha Farhadfar, Mohamed A. Kharfan-Dabaja, Carlos Litovich, Sonali M. Smith, Vaishalee P. Kenkre, Bradley M. Haverkos, Taiga Nishihori
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood
Autor:
Monalisa Ghosh, Ranjan Tiwari, Catherine Thieblemont, Andy I. Chen, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Martin Dreyling, Michael Dickinson, Stephen J. Schuster, Charalambos Andreadis, Aisha Masood, Nathan Fowler
Publikováno v:
Blood. 138:3533-3533
Background: Follicular lymphoma (FL) is the second most frequently diagnosed Non-Hodgkin lymphoma subtype in Western countries. Patients often undergo multiple lines of therapy over many years throughout the course of their disease with worse surviva
Autor:
Andrés J.M. Ferreri, C Lobetti Bodoni, Monalisa Ghosh, Fritz Offner, Charalambos Andreadis, Pier Luigi Zinzani, Arne Kolstad, Martin Dreyling, Catherine Thieblemont, Julio C. Chavez, Stephen J. Schuster, P. Joy Ho, Piers Em Patten, Peter A. Riedell, Bastian von Tresckow, Marie José Kersten, Andreas Viardot, Leslie Popplewell, Ram Malladi, Aisha Masood, Michael Dickinson, Emmanuel Bachy, Joaquin Martinez-Lopez, Andreas L. Petzer, Aiesha Zia, Loretta J. Nastoupil, José A. Pérez-Simón, Hideo Harigae, Nathan Fowler, Takanori Teshima, Koji Kato, Jason Butler, Andy I. Chen, Joseph P. McGuirk
Publikováno v:
Blood. 138:131-131
Background: Follicular lymphoma is an indolent disease with a continuous relapsing pattern and typically requires multiple lines of therapy. Novel therapies such as tisagenlecleucel are being investigated to improve outcomes. Primary analysis of the
Autor:
Joseph P. McGuirk, Januario E. Castro, Jae H. Park, Bahram Valamehr, Monica Diaz, Andy I. Chen, Yu-Waye Chu, Nitin Jain
Publikováno v:
Blood. 136:15-16
Background: Autologous T cells engineered to express a chimeric antigen receptor (CAR) targeting the B-cell lineage antigen CD19 (CAR19) in patients with relapsed/refractory (r/r) aggressive B-cell lymphomas (BCL) and pre-B acute lymphoblastic leukem
Autor:
Paula Perkins, Andy I. Chen, Jordan Gauthier, Cameron J. Turtle, Brandon Hayes-Lattin, Levanto Schachter, Jessie Myers, David G. Maloney, Aisling Cearley, Staci Williamson, Mazyar Shadman, Mohamed L. Sorror, Sarah J. Nagle, Angela Kirk, Richard T. Maziarz
Publikováno v:
Journal of Clinical Oncology. 39:7532-7532
7532 Background: CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells achieve high response rates in patients (pts) with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL), but are limited by cytokine release s
Autor:
Bruce D. Cheson, Daniel Lebovic, Andre Goy, Priya Agarwal, Surai Jones, Hsin Ju Hsieh, Robert Kahn, Yu Waye Chu, Dan Lu, Julie E. Chang, Mark Brunvand, Ephraim P. Hochberg, Sreeni Yalamanchili, Ranjana H. Advani, Randall C. Dere, Andy I. Chen
Publikováno v:
Clinical Cancer Research. 23:1167-1176
Purpose: Pinatuzumab vedotin is an antibody–drug conjugate with the potent antimicrotubule agent monomethyl auristatin E (MMAE) conjugated to an anti-CD22 antibody via a protease-cleavable linker. This phase I study determined its recommended phase